- Reports Q1 (Jan) earnings of $0.45 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.44; revenues fell 10.4% year/year to $11.41 bln vs the $12.05 bln Capital IQ Consensus.
- Enterprise Group revenue was $6.3 billion, down 12% year over year, down 6% when adjusted for divestitures and currency, with a 12.7% operating margin. Servers revenue was down 12%, down 11% when adjusted for divestitures and currency, Storage revenue was down 13%, down 12% when adjusted for divestitures and currency, Networking revenue was down 33%, up 6% when adjusted for divestitures and currency, and Technology Services revenue was down 2%, up 4% when adjusted for divestitures and currency.
- Enterprise Services revenue was $4.0 billion, down 11% year over year, down 6% when adjusted for divestitures and currency, with a 7.0% operating margin. Infrastructure Technology Outsourcing revenue was down 8%, down 7% when adjusted for divestitures and currency, and Application and Business Services revenue was down 17%, down 3% when adjusted for divestitures and currency.
- Software revenue was $721 million, down 8% year over year, down 1% when adjusted for divestitures and currency, with a 21.4% operating margin. License revenue was down 9%, down 2% when adjusted for divestitures and currency, Support revenue was down 9%, down 2% when adjusted for divestitures and currency, Professional Services revenue was down 7%, down 5% when adjusted for divestitures and currency, and Software-as-a-service (SaaS) revenue was up 4%, up 6% when adjusted for divestitures and currency.
- Financial Services revenue was $823 million, up 6% year over year, net portfolio assets were up 2%, and financing volume was down 10%. The business delivered an operating margin of 9.5%.
- Co issues downside guidance for Q2, sees EPS of $0.41-0.45, excluding non-recurring items, vs. $0.45 Capital IQ Consensus Estimate.
- Co issues in-line guidance for FY17, lowers EPS to $1.88-1.98 from $2.00-2.10, excluding non-recurring items, vs. $1.93 Capital IQ Consensus. Three significant headwinds have developed since Hewlett Packard Enterprise provided its original fiscal 2017 outlook at its Securities Analyst Meeting in October 2016: increased pressure from foreign exchange movements, higher commodities pricing, and some near-term execution issues. Given these challenges, the company is reducing its FY17 outlook by $0.12 in order to continue making the appropriate investments to secure the long-term success of the business.
Closing Market Summary: Dow Records 10th Consecutive Record CloseInvestors hurdled news headline after news headline on Thursday, but still drove the Dow (+0.2%) to its tenth consecutive record close, a feat that has not been achieved since 1987, when the price-weighted average recorded 12 consecutive record closes. The benchmark S&P 500 (unch) finished flat while the Nasdaq (-0.4%) and the small-cap Russell 2000 (-0.6%) couldn't keep pace.
Early on Thursday morning, Treasury Secretary Steven Mnuchin said that he anticipates the new administration's tax reform plan to to pass through congress before the August recess.
Mr. Mnuchin's timeline may have cooled the recent bullish sentiment surrounding President Trump's upcoming "phenomenal" tax-related announcement, a promise which sent the stock market on its most recent rally. However, the financial sector (+0.1%), which has led post-election rally on promises of deregulation and tax reform, finished Thursday with a small gain.
On the earnings front, Tesla (TSLA 255.99, -17.52) disappointed investors with a wider than expected loss per share, but the automaker did announce that the mass-market electric Model 3 sedan is on track for initial production in July.
Similarly, L Brands (LB 48.94, -9.19) finished Thursday lower, plummeting 15.8%, after the company's below-consensus guidance overshadowed better than expected earnings. LB's slide weighed on the SPDR S&P 500 Retail ETF (XRT 43.10, -1.03), which ended lower by 2.3%, while the consumer discretionary sector (-0.7%) also underperformed.
Technology (-0.1%) was plagued by a poor showing from chipmakers, evidenced by the 1.6% decrease in the PHLX Semiconductor Index. The semiconductor industry was led lower by NVIDIA (NVDA 100.49, -10.27). The company plunged 9.3% after analysts from both BMO Capital and Instinet downgraded NVDA shares on Thursday morning. To be fair, NVDA shares skyrocketed 223.9% in 2016, so a pullback of this magnitude isn't really all that surprising.
However, a 8.6% jump in shares of HP (HPQ 17.60, +1.40) put a lid on the tech sector's loss. The company's spike followed its most recent earnings report, which showed better than expected top and bottom lines.
Industrials (-0.8%) finished Thursday at the bottom of the leaderboard amid growing speculation of a potential delay in the implementation of the Trump administration's infrastructure plan. Likewise, the materials sector closed lower by 0.6%.
On a positive note, the energy sector finished 0.5% higher thanks to crude oil's solid performance. The energy component finished up 1.6% at $54.47/bbl following Thursday's EIA crude inventory report, which showed a build of 0.6 million barrels while the consensus called for a build of about 3.475 million barrels. Today's EIA report confirmed yesterday's bullish API reading.
On the countercyclical side, health care (+0.7%) also closed in the green. Outside of the biotechnology industry, health care components showed broad strength. It is also worth pointing out that Former House Speaker John Boehner said a full repeal and replacement of the Affordable Care Act is "not going to happen." Considering that Mr. Boehner led Republican opposition to the Affordable Care Act for years, his comments are particularly notable.
The remaining sectors--consumer staples, utilities, telecom services, and real estate--all closed with gains between 0.3% and 1.1%.
U.S. Treasuries finished Thursday modestly higher. The benchmark 10-yr yield closed three basis points lower at 2.38%.
Today's economic data included Initial Claims and December FHFA Housing Price Index:
- The latest weekly initial jobless claims count totaled 244,000 while the consensus expected a reading of 242,000. Today's tally was above the revised prior week count of 238,000 (from 239,000). As for continuing claims, they declined to 2.060 million from the revised count of 2.077 million (from 2.076 million).
- The key takeaway from this report is that it covers the period in which the survey for the February Employment Situation report was conducted, and given the low level of claims, it will likely feed a belief that nonfarm payrolls are apt to increase by 200,000+ again.
- The FHFA Housing Price Index for December rose 0.4%, which followed a revised increase of 0.7% in November (from 0.5%). The reading was in line with consensus (+0.4%).
- The key takeaway from the report is that high prices and limited inventory continue to compress the affordability factor for prospective buyers, and have prevented existing home sales from being even stronger.
On Friday, Investors will receive January New Home Sales (consensus 566,000) and the final reading of the University of Michigan Sentiment Index for February (consensus 95.8). Both reports will be releases at 10:00 am ET.
- Nasdaq Composite +8.4% YTD
- S&P 500 +5.6% YTD
- Dow Jones Industrial Average +5.3% YTD
- Russell 2000 +2.8% YTD
- Reports Q4 (Dec) loss of $0.16 per share, excluding non-recurring items, $0.08 worse than the Capital IQ Consensus of ($0.08); revenues rose 31.6% year/year to $300 mln vs the $294.95 mln Capital IQ Consensus.
- Co issues downside guidance for FY17, sees FY17 revs of $1.25-1.30 bln vs. $1.32 bln Capital IQ Consensus with $30-70 mln in non-GAAP net loss.
- "our regulatory filings for approval of Brineura, for the treatment of Batten disease, were accepted and validated in both the U.S. and EU. With the Prescription Drug User Fee Act (PDUFA) goal date for an FDA approval decision of April 27, 2017, we hope to have an approved treatment option for this devastating childhood disease in the near future." Mr. Bienaimé continued, "In addition, in 2016 we moved our vosoritide program forward based on Phase 2 results in children ages 5-14 with achondroplasia. At the end of 2016, we initiated a one-year, randomized, placebo-controlled Phase 3 study in children with achondroplasia ages 5-14 using a daily 15µg/kg dose. We recently provided encouraging preliminary results with our earliest clinical-stage program BMN 250 for the treatment of MPS IIIB, or Sanfilippo Syndrome, Type B. We are now moving to the expansion phase of the development program that will assess the impact of treatment with BMN 250 on the neurocognitive function in this rapidly progressive pediatric brain disease. Finally, in addition to the filing of the BLA for pegvaliase for the treatment of phenylketonuria expected in the second quarter of 2017, we expect to start to turn the corner to profitability with the achievement of positive non-GAAP results for the full year 2017."
- BMN 270 gene therapy product for hemophilia A: Today the Company announced that in the ongoing Phase 1/2 study, the three additional patients to be enrolled in the study will be dosed at the same 4 x 1013 vg/kg dose as the 3 most recently enrolled patients. Consistent with the dosing regimen of the 3 most recently enrolled patients, the 3 additional patients will be dosed without prophylactic corticosteroids. In October 2016, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom approved continued enrollment into the open-label Phase 1/2 study of BMN 270 for severe hemophilia A. The agency also approved the Company's proposed amendments to the study, which included eliminating the requirement for prophylactic corticosteroids and increasing potential additional enrollment from up to three additional patients to up to six additional patients. In the fourth quarter of 2016, three patients were dosed at 4 x 1013 vg/kg with BMN 270.
Closing Commodities: Crude closes near Tuesday's 7-week high ahead of tomorrow's rig count; natural gas extends gains & closes near the midpoint of its early morning rally post-EIA
- Crude closed just under Tuesday's 7-week high after EIA reported a smaller-than-expected build in crude & a larger-than-expected draw in gas inventories, compared to Consensus
- April crude oil futures rose $0.86 (+1.6%) to $54.47/barrel
- Reminder: Baker Hughes rig count data will be released tomorrow at 1 pm ET.
- EIA highlights:
- Crude oil inventories had a build of +0.6 mln barrels (consensus called for a build of about +3.475 mln barrels).
- Gasoline inventories had a draw of -2.6 mln barrels (consensus called for a draw of -0.888 mln barrels).
- Distillate inventories had a draw of -4.9 mln barrels.
- Natural gas extended last session's gains & closed near the midpoint of its early morning rally after EIA reported a draw roughly in-line with expectations
- April natural gas closed $0.05 higher (+1.9%) at $2.75/MMBtu
- EIA highlights:
- Natural gas inventory showed a draw of -89 bcf vs expectations for inventory to be a draw between -85 to -93 bcf.
- Working gas in storage was 2,356 Bcf as of Friday, February 17, 2017, according to EIA estimates.
- Stocks were 261 Bcf less than last year at this time and 156 Bcf above the five-year avg of 2,200 Bcf.
- At 2,356 Bcf, total working gas is within the five-year historical range.
- In precious metals, gold & silver erased all of yesterday's losses on continued weakness in the dollar index
- April gold ended today's session up $17.90 (+1.5%) to $1251.60/oz
- Mar silver closed today's session $0.19 higher (+1.1%) at $18.13/oz
- The dollar index was -0.2% around the 100.99 level, provided support to precious metals
- Commodities, as measured by the Bloomberg Commodity Index, were -0.2% around the 87.37 level
- Base metal copper dropped 3.3% & closed down $0.09 around the $2.64/lb level